Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecologic malignancies.

J D Nash, R C Young

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1991
    PubMed
    Summary
    This summary is machine-generated.

    The preferred treatment for advanced ovarian cancer uses cisplatin and cyclophosphamide. Carboplatin offers similar results with less toxicity, and taxol shows promise for resistant cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Direct observations of submarine melt and subsurface geometry at a tidewater glacier.

    Science (New York, N.Y.)·2019
    Same author

    Self-organized criticality in geophysical turbulence.

    Scientific reports·2019
    Same author

    Healthy People 2020: assessment of pharmacists' priorities.

    Public health·2018
    Same author

    Eating behavior and body weight: physiological influences.

    American journal of health promotion : AJHP·2012
    Same author

    Eating behavior and body weight: psychosocial influences.

    American journal of health promotion : AJHP·2012
    Same author

    Vulvar cancer.

    Surgical oncology clinics of North America·1998
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Gynecologic Oncology
    • Medical Oncology
    • Clinical Trials

    Background:

    • Cisplatin and cyclophosphamide are standard for advanced epithelial ovarian cancer.
    • Maximal dose intensity is crucial but lacks rigorous validation.
    • Carboplatin shows promise as a less toxic alternative to cisplatin.

    Purpose of the Study:

    • To review current treatment strategies for advanced ovarian cancer.
    • To evaluate novel agents and delivery methods.
    • To discuss management of early-stage ovarian cancer and other gynecologic malignancies.

    Main Methods:

    • Review of clinical trial data and treatment outcomes.
    • Analysis of response rates and toxicity profiles.
    • Evaluation of emerging therapies including taxol and intraperitoneal delivery.

    Related Experiment Videos

    Main Results:

    • Carboplatin demonstrates equivalent response rates to cisplatin with reduced toxicity.
    • Taxol shows promising responses in platinum-resistant and heavily pre-treated patients.
    • Surgery alone is effective for low-risk early-stage ovarian cancer; adjuvant therapy benefits high-risk groups.

    Conclusions:

    • Carboplatin is a viable alternative to cisplatin in advanced ovarian cancer.
    • Taxol represents a promising new agent for salvage therapy.
    • Further research is needed to define optimal regimens and roles for new therapies.